Lung cancer working group report

Japanese Journal of Clinical Oncology

Volumn 40, Issue SUPPL. 1, 2010, Pages

  Saijo, Nagahiro ^a   Fukuoka, Masahiro ^a   Thongprasert, Sumitra ^b   Ichinose, Yukito ^c   Mitsudomi, Tetsuya ^d   Mok, Tony Shu Kam ^e   Ohe, Yuichiro ^f   Park, Keunchil ^g   Wu, Yi Long ^h  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CHIANG MAI UNIVERSITY   (Thailand)

^c NATIONAL KYUSHU CANCER CENTER   (Japan)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^f Thoracic Oncology   (South Korea)

^g Sungkyunkwan University School of Medicine   (South Korea)

^h GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

EGFR mutation; Ethnic differences; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; PEMETREXED;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; DIARRHEA; DRUG METABOLISM; ETHNIC DIFFERENCE; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; ASIA; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; LUNG NEOPLASMS; PRACTICE GUIDELINE; PROTO ONCOGENE;

ASIA; CARCINOMA, NON-SMALL-CELL LUNG; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; PRACTICE GUIDELINES AS TOPIC;

EID: 77957280882     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq121     Document Type: Article

References (29)

1. Mitsudomi T, Kosaka T, Endoh H, Shinoda M, Takahashi T, Yatabe Y, et al. Mutations of the EGFR gene predict prolonged survival after gefitinib treatment in patients with NSCLC with postoperative recurrence. J Clin Oncol 2005;23:2513-20.
2. Takano T, Ohe Y, Sakamoto H, Sakiyama T, Yoshida T, Tamura T, et al. Epidermal growth factor receptor gene mutation and increase copy numbers predicts gefitinib sensitivity in patients with recurrent non-small lung cancer. J Clin Oncol 2005;23:6829-37.
3. Ando Y, Saka H, Ando M, Saitoh S, Shimokata K, Hasegawa Y, et al. Polymorphisms of UDP-glucurronosyl transferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000;60:6921-6.
4. Ratain MJ. From bedside to bench to bedside to clinical practice: an odyssey with irinotecan. Clin Cancer Res 2006;12:1658-60.
5. Minami H, Sai K, Saeki M, Yoshida T, Ohtsu A, Saijo N, et al. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics 2007;17:497-504.
6. Schiller JH, Harrington D, Krook J, Zhu J, Johnson DH, et al., Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8.
7. Ohe Y, Ohashi Y, Kubota K, Saijo N, Ariyoshi Y, Fukuoka M, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cicplatin plus gemcitabine, and cicplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007;18:317-23.
8. Saijo N. Recent trends in the treatment of advanced lung cancer. Cancer Sci 2006;97:448-52.
9. Saijo N. Advances in the treatment of non-small cell lung cancer. Cancer Treat Rev 2008;34:521-6.
10. NCCN Clinical Practice Guideline in Oncology. Non: Small cell lung cancer V.I, 2010. National comprehensive Network. www.nccn.org.
11. NCCN Clinical Practice Guideline in Oncology. Non-small all lung cancer V2 2008 Korean guideline. www.nccn.asia.org.
12. NCCN Clinical Practice Guideline in Oncology. Non-small cell lung cancer V2 2008;. www.nccn.china.org.
13. Lung Cancer Guideline based on EBM 2003. Report of study group for Lung Cancer guideline based on EBM. Kanehara Shuppan, 2003.
14. Lung Cancer Guideline based on EBM 2005. Report of Jpn Soc. Lung Cancer, Kanehara Shuppan, 2005.
15. Lord RV, Brabender J, Gandara D, Danenberg KD, Danenberg PV, Rosell R, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002;8:2286-91.
16. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC in lung cancer. NEnglJMed 2007;356:800-8.
17. Olaussen KA, Dunant A, Fouret P, Brambilla E, Tursz T, Le Chevalier T, Soria JC, et al., IALT Bio Investigators. IALT Bio investigators DNA repair by ERCC1 in non-small cell lung cancer and cisplatin based adjuvant chemotherapy. N Engl J Med 2006;355:983-91.
18. Fouret P, Planchard D, M Endiboure J, et al. MSH2 and adjuvant cisplatin based chemotherapy in non-small cell lung cancer. J Clin Oncol 2009;27. Abstract CRA 7502.
19. Einhorn LH. First line chemotherapy for non-small cell lung cancer: is there a superior regimen based on histology? J Clin Oncol 2008;26:3485-6.
20. Scagliotti GV, Parikh P, von Pawel J, Simms L, Sugarman KP, Gandara D, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced stage non-small cell lung cancer. J Clin Oncol 2008;26:3543-51.
21. Hanna N, Shepherd FA, Fossella FV, Paoletti P, Einhorn L, Bunn PA, Jr, et al. Randomized phase III trial of pemetrexed vs docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97.
22. Ciuleanu TE, Brodowicz T, Belani CP, et al. Maintenance pemetrexed plus supportive care versus placebo plus BSC: a phase III study. J Clin Oncol 2008;26. Abstract 8011.
23. Scagliotti G, Hanna N, Fossella F, Peterson P, Simms L, Shepherd FA, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009; 14:253-63.
24. Herbst RS, Maddox AM, Rothenberg ML, Averbuch SD, Ochs J, LoRusso PM, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002;20:3815-25.
25. Fukuoka M, Yano S, Giaccone G, Feyereislova A, Dong RP, Baselga J, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003;21:2237-46.
26. Sayo N, Takeuchi M, Kunitoh H. Reasons for response differences seen in the V15-32, INTEREST and IPASS trial. Nat Rev Clin Oncol 2009;6:287-94.
27. Gandara DR, Kawaguchi T, Crowley J, Saijo N, Fukushima M, Mack PC, et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol 2009;27:3540-6.
28. Sangha R, Lara PN, Jr, Adjei AA, Schiller JH, Vokes EE, Gandara DR, et al. Cooperative group research endevours in small-cell lung cancer: current and future directions. Clin Lung Cancer 2009;10: 322-30.
29. AzzoliCG,BakerS,Jr,TeminS,StrawnJR,TrentD,GiacconeG, et al. American Society of Clinical Oncology. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009;27: 6251-66.